New Drug Treats Advanced Prostate Cancer

But severe allergic reactions are possible

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, Dec. 1, 2003 (HealthDayNews) -- The U.S. Food and Drug Administration has approved a new drug for men with advanced prostate cancer who don't benefit from other treatments.

The Praecis Pharmaceuticals drug Plenaxis (abarelix) will be restricted to only 5 percent to 10 percent of prostate cancer patients -- those who can't tolerate other hormone therapies and who have refused surgical castration, the FDA says.

The restrictions have been imposed because Plenaxis users are at risk of a life-threatening allergic reaction that could cause a dangerous drop in blood pressure. The agency says users should be monitored for at least 30 minutes after being injected with the drug.

Plenaxis is among a group of medicines called gonadotropin-releasing hormone antagonists that are designed to lower levels of the male hormone testosterone -- a key factor in most prostate cancer growth. In 12-week clinical trials involving 81 men, the drug relieved bone pain and helped ease urinary problems. Common side effects included hot flashes, sleep disturbances, pain and constipation.

As a condition of FDA approval, the drug's manufacturer has agreed not to sell it through retail pharmacies, but directly to doctors and hospitals.

For more information, visit the National Cancer Institute.

--

Last Updated:

Related Articles